Aminoglutethimide and metyrapone in the management of Cushing's syndrome
Citations Over TimeTop 23% of 1985 papers
Abstract
Fifteen patients with endogenous Cushing's syndrome were treated with metyrapone and/or amino-glutethimide. The duration of the therapy varied from 19 up to 365 days. In patients with Cushing's disease, metyrapone (0.5-2.5 g/day) and aminoglutethimide (0.5-1.5 g/day) seemed equally effective in reducing the cortisol excretion (54 +/- 9 vs 40 +/- 7%). The majority of these patients also showed a clinical improvement. In 1 patient with adrenal adenoma, metyrapone induced a remission. In another patient with adrenocortical cancer, and in 2 with the ectopic ACTH syndrome, the cortisol excretion was significantly reduced by the combination of metyrapone and aminoglutethimide but no obvious clinical improvement was observed. Side effects i.e. rash and pruritus attributed to aminoglutethimide was seen in 3 patients which necessitated the omission of treatment in 2. On metyrapone a moderate hypertrichosis was observed in 1 patient. In conclusion both metyrapone and aminoglutethimide were useful as adjunctive therapy in Cushing's syndrome.
Related Papers
- Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy.(1976)
- → Aminoglutethimide and metyrapone in the management of Cushing's syndrome(1985)53 cited
- → Adrenostatische Therapie mit Metyrapon und Aminoglutethimid beim ACTH-abhängigen Cushing-Syndrom(2008)3 cited
- [Clinical usefulness of pharmacological treatment of Cushing's syndrome].(1994)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)